Valuation : PharmaEngine, Inc.

Market Cap 839.08Cr 26Cr 23Cr 21Cr 20Cr 37Cr 2.51TCr 37Cr 253.99Cr 99Cr 1.28TCr 99Cr 97Cr 4.24TCr P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 371.61Cr 12Cr 10Cr 9.51Cr 8.67Cr 16Cr 1.11TCr 16Cr 112.48Cr 44Cr 566.11Cr 44Cr 43Cr 1.88TCr EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.29%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-1.02%
1 week-1.35%
Current month-1.02%
1 month-4.89%
3 months+8.96%
6 months-10.15%
Current year-17.05%
1 week 58.3
Extreme 58.3
60.8
1 month 58
Extreme 58
64.7
Current year 53
Extreme 53
74
1 year 53
Extreme 53
74.4
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 19/01/2018
Director/Board Member - 15/05/2018
Director/Board Member - 13/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-1.35%-13.10%-32.80% 27Cr
+0.21%-1.70%+1.90%+18.18% 4.98TCr
+2.09%-0.81%+452.73%+517.81% 4.41TCr
-1.09%-0.73%+35.40%+16.04% 4.3TCr
-0.26%-3.58%+17.19%+72.80% 4.09TCr
-0.48%-3.09%+17.78%+49.80% 3.31TCr
-1.81%-5.94%+22.65%+115.79% 1.66TCr
-1.06%+3.29% - - 1.73TCr
-1.35%-2.32%+10.40%+25.90% 1.46TCr
-2.05%-5.44%+72.89%+36.51% 1.38TCr
Average -0.65%-1.76%+68.65%+91.12% 2.73TCr
Weighted average by Cap. -0.19%-1.79%+95.21%+124.28%

Financials

2024 2025
Net sales 252.33Cr 7.96Cr 6.87Cr 6.46Cr 5.89Cr 11Cr 755.69Cr 11Cr 76Cr 30Cr 384.4Cr 30Cr 29Cr 1.27TCr 91Cr 2.88Cr 2.48Cr 2.33Cr 2.13Cr 4Cr 272.95Cr 4.02Cr 28Cr 11Cr 138.85Cr 11Cr 11Cr 460.39Cr
Net income 175.1Cr 5.53Cr 4.77Cr 4.48Cr 4.08Cr 7.68Cr 524.4Cr 7.72Cr 53Cr 21Cr 266.75Cr 21Cr 20Cr 884.51Cr 39Cr 1.22Cr 1.06Cr 99.25L 90.42L 1.7Cr 116.09Cr 1.71Cr 12Cr 4.57Cr 59Cr 4.59Cr 4.49Cr 195.81Cr
Net Debt -385.37Cr -12Cr -10Cr -9.87Cr -8.99Cr -17Cr -1.15TCr -17Cr -116.65Cr -45Cr -587.07Cr -46Cr -45Cr -1.95TCr -467.47Cr -15Cr -13Cr -12Cr -11Cr -21Cr -1.4TCr -21Cr -141.5Cr -55Cr -712.15Cr -55Cr -54Cr -2.36TCr
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
01/26/01 NT$58.40 -1.02% 2,05,230
31/26/31 NT$59.00 -1.67% 2,03,597
28/26/28 NT$60.00 -0.83% 1,59,389
27/26/27 NT$60.50 +0.67% 2,00,382
26/26/26 NT$60.10 +1.86% 2,31,802
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock